Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from Catalent ( (CTLT) ).
Catalent has been acquired by Novo Holdings in an all-cash transaction valued at $16.5 billion, transitioning the company to private ownership. This move is set to strengthen Catalent’s position as a global service provider in the pharma and biotech industry, with a focus on delivering exceptional outcomes for customers and patients. The acquisition entails Catalent’s delisting from the New York Stock Exchange, and the transfer of certain Catalent assets to Novo Nordisk A/S. The leadership, including CEO Alessandro Maselli, remains in place to drive future growth under Novo Holdings’ support.
More about Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) focused on developing, manufacturing, and supplying products for the pharmaceutical, biotech, and consumer health sectors. With expertise in development sciences, delivery technologies, and manufacturing, Catalent accelerates development programs and launches numerous new products annually from its over 40 global sites.
YTD Price Performance: 41.29%
Average Trading Volume: 2,243,861
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $11.52B
For detailed information about CTLT stock, go to TipRanks’ Stock Analysis page.
